Literature DB >> 18557746

Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera.

Holger Cario1, Klaus Schwarz, Jan M Herter, Vladimir Komrska, Mary F McMullin, Milen Minkov, Charlotte Niemeyer, Dagmar Pospisilova, Harald Reinhard, Klaus-Michael Debatin, Heike L Pahl.   

Abstract

The clinical, haematological, molecular and treatment data of eight paediatric patients with polycythemia vera (PV) were collected prospectively. One patient developed PV after treatment for large-cell anaplastic lymphoma. Budd-Chiari syndrome was diagnosed in two patients, necessitating orthotopic liver transplantation in one and transjugular portosystemic shunting in the other. The remaining patients presented with non-specific symptoms. Endogenous erythroid colonies were detected in all cases examined. The JAK2(V617F) mutation was found in six patients; two patients displayed JAK2 exon 12 mutations, including one novel mutation (JAK2(H538-K539delinsI)). CD177 (PRV-1) mRNA expression was increased in three of five patients tested.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18557746      PMCID： PMC4120186          DOI： 10.1111/j.1365-2141.2008.07220.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  12 in total

1.  [Ascites and splenomegaly in childhood. Freiburger gastroenterology discussions].

Authors:  M Roth; K Haag; T Krause; U Blum; U Hellerich
Journal:  Med Klin (Munich)       Date:  1990-09-15

2.  Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders.

Authors:  Jason M Melear; Robert M Goldstein; Marlon F Levy; Ernesto P Molmenti; Barry Cooper; George J Netto; Goran B Klintmalm; Marvin J Stone
Journal:  Transplantation       Date:  2002-10-27       Impact factor: 4.939

3.  [Budd-Chiari syndrome associated with chronic myeloproliferative syndromes: analysis of 6 cases].

Authors:  F Cobo; F Cervantes; J C García-Pagán; J Bosch; C Rozman; E Montserrat
Journal:  Med Clin (Barc)       Date:  1996-11-16       Impact factor: 1.725

4.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  Polycythemia vera in a child following treatment for acute lymphoblastic leukemia.

Authors:  Nadia D Sutherland; Regino Gonzalez-Peralta; Vonda Douglas-Nikitin; Stephen P Hunger
Journal:  J Pediatr Hematol Oncol       Date:  2004-05       Impact factor: 1.289

6.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

7.  The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.

Authors:  Luciana Teofili; Fiorina Giona; Maurizio Martini; Tonia Cenci; Francesco Guidi; Lorenza Torti; Giovanna Palumbo; Angela Amendola; Giuseppe Leone; Robin Foà; Luigi M Larocca
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

8.  Familial polycythemia vera with Budd-Chiari syndrome in childhood.

Authors:  Holger Cario; Heike L Pahl; Klaus Schwarz; Christoph Galm; Martin Hoffmann; Martin Burdelski; Elisabeth Kohne; Klaus-Michael Debatin
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

9.  PRV-1 mRNA expression discriminates two types of essential thrombocythemia.

Authors:  M Griesshammer; S Klippel; E Strunck; S Temerinac; U Mohr; H Heimpel; H L Pahl
Journal:  Ann Hematol       Date:  2004-03-18       Impact factor: 3.673

10.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245
View more
  4 in total

1.  Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome.

Authors:  Mehmet Enes Coskun; Sue Height; Anil Dhawan; Nedim Hadzic
Journal:  BMJ Case Rep       Date:  2017-07-14

2.  Myeloproliferative Neoplasms in Children.

Authors:  Inga Hofmann
Journal:  J Hematop       Date:  2015-08-02       Impact factor: 0.196

Review 3.  Clinical and hematological presentation of children and adolescents with polycythemia vera.

Authors:  Holger Cario; Mary Frances McMullin; Heike L Pahl
Journal:  Ann Hematol       Date:  2009-05-26       Impact factor: 3.673

Review 4.  Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.

Authors:  Douglas Tremblay; Abdulraheem Yacoub; Ronald Hoffman
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-26       Impact factor: 3.722
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.